# AMT-116

Source: https://onco.cc/drugs/amt-116/  
OnCo record `amt-116` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AMT-116 is an antibody-drug conjugate from Multitude Therapeutics Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.

## Summary

AMT-116 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Multitude Therapeutics Inc., in non-small-cell lung cancer, small-cell lung cancer. An antibody-drug conjugate, as described in the registry record: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: AMT-116
- Modality: Antibody-drug conjugate
- Mechanism: An antibody-drug conjugate, as described in the registry record: an antibody against a tumour surface protein carries a cytotoxic payload into the cell.

## Sources

- ClinicalTrials.gov: trials of AMT-116: https://clinicaltrials.gov/search?intr=AMT-116

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Multitude Therapeutics](https://onco.cc/companies/multitude-therapeutics/)
- trials: [AMT-116 in Combination With AK112 in Patients With Lung Cancer](https://onco.cc/trials/nct07590531/), [AMT-116 in Patients with Solid Tumors](https://onco.cc/trials/nct06782334/)

---
JSON: https://onco.cc/api/v1/entities/amt-116.json